Before the Claim Arrives: An Employer’s Guide to Cell and Gene Therapy Readiness

Cepheid’s Xpert Respiratory Panel, which tests one swab for nine viruses and four bacteria, is now certified for sale in Europe under the IVDR.

A study of 1,068 adults found whole-blood NAD fell in those with cardiovascular disease and hypertension but did not decline with age.

Adding Sunharbo (asundexian), a first-in-class factor XI inhibitor, to single or dual antiplatelet therapy reduces ischemic stroke risk without increasing the risk of major bleeding.

In this discussion, University College London colleagues Joshua Stott, Ph.D., professor of aging and clinical psychology and research assistant Lucy Corrigan, who led the work while at the University of Liverpool, talk about their recent meta-analysis linking ADHD to a higher risk of death from all causes, including suicide, injury and natural causes.

The American Academy of Sleep Medicine’s first update since 2007 favors generic drugs, caffeine, light and naps, and advises against benzodiazepines.

People with advanced Parkinson’s disease who also have a sleep disorder cost about $50,000 a year to treat, $13,000 more than similar patients without one, according to an AbbVie-funded claims analysis.

Geisinger Health Plan President Jeremy Gaskill says the possibility that a growing number of patients won't have health insurance could put tremendous financial pressure on the plan's providers.

γδ T cells infiltrate small cell lung cancer tumors and can kill them without the MHC-I machinery these tumors typically switch off, and patients with more of them trended toward longer survival on anti-PD-L1 immunotherapy.